Immutep Completes Recruitment of 2
nd line PD-1/PD-L1 refractory NSCLC Patients
in TACTI-002
• Last 2
nd line PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC) patient has been enrolled and
safely dosed, completing recruitment of Stage 2 of Part B
• Total of 154 patients out of up to 183 patients (84%) now participating in the expanded trial, with
recruitment continuing for the expansion stage of Part A
• Further data expected to be reported in calendar year 2021 or early calendar year 2022
Media, page-119
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.010(3.33%) |
Mkt cap ! $421.2M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 28.5¢ | $751.3K | 2.589M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 307462 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 118494 | 4 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |